Basalioma after amiodarone therapy-not only in Britain

Hall, Mark A.; Annas, Anita; Nyman, K; Talme, Toomas; Emtestam, Lennart

doi:10.1111/j.1365-2133.2004.06193.x

Cited by 15 publications

(22 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possible connection between amiodarone‐induced photosensitivity and BCC was raised in a report on five patients who developed BCCs during amiodarone treatment 9,10 . All five cases were on long‐term amiodarone treatment and, like our case, developed basaliomas 3–5 years after starting treatment with the drug; a number of these BCCs developed within a short period of time (months) on both sun‐exposed and unexposed skin 9,10 .…”

Section: Discussionmentioning

confidence: 64%

Amiodarone‐induced skin pigmentation and multiple basal‐cell carcinomas

Maoz¹,

Dvash²,

Brenner³

2009

Int J Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 64%

Amiodarone‐induced skin pigmentation and multiple basal‐cell carcinomas

Maoz¹,

Dvash²,

Brenner³

2009

Int J Dermatology

View full text Add to dashboard Cite

“…In previous case reports,13‐15, 18, 19 cancers typically developed after regular use of amiodarone for 2 years to 5 years, suggesting that a latency period and high cumulative doses might be necessary for the development of amiodarone‐associated malignancies. On the Kaplan‐Meier analysis performed in the current study, the overall cancer incidences of patients with low, intermediate, and high cDDDs were found to be significantly different.…”

Section: Discussionmentioning

confidence: 95%

“…In addition, amiodarone has been reported to enhance the effects of radiation on the skin and mucosa,23 and thus possibly accentuate the effects of radiation carcinogenesis. Several case reports have shown evidence of a plausible correlation between amiodarone and malignancies in humans 6–19. Furthermore, a meta‐analysis of 15 randomized controlled trials, 4 of which reported cancer deaths, unexpectedly revealed that there were more cancer deaths in patients assigned to treatment with amiodarone compared with patients in the control groups (0.8% [13 of 1609 patients] vs 0.3% [4 of 1597 patients]; P = .0501) 24…”

Section: Discussionmentioning

confidence: 99%

“…[6][7][8][9][10][11][12][13][14][15][16][17][18][19] Furthermore, a meta-analysis of 15 randomized controlled trials, 4 of which reported cancer deaths, unexpectedly revealed that there were more cancer deaths in patients assigned to treatment with amiodarone compared with patients in the control groups (0.8% [13 of 1609 patients] vs 0.3% [4 of 1597 patients]; P ¼ .0501). 24 In previous case reports, [13][14][15]18,19 cancers typically developed after regular use of amiodarone for 2 years to 5 years, suggesting that a latency period and high cumulative doses might be necessary for the development of amiodarone-associated malignancies. On the Kaplan-Meier analysis performed in the current study, the overall cancer incidences of patients with low, intermediate, and high cDDDs were found to be significantly different.…”

Section: Discussionmentioning

confidence: 99%

“…In postmarketing surveillance, the Food and Drug Administration reported the development of lung masses, thyroid cancer, and skin cancer after treatment with amiodarone 5. Some case reports indicated that amiodarone might increase the risk of pulmonary masses,6‐12 thyroid cancer,13‐15 and skin cancer 16‐19. In addition, a meta‐analysis of randomized trials unexpectedly revealed a borderline significant increase in cancer mortality among patients assigned to the amiodarone group.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Amiodarone and the risk of cancer

Chou

et al. 2013

Cancer

View full text Add to dashboard Cite

BACKGROUND:In postmarketing surveillance, the US Food and Drug Administration has reported the development of lung masses, thyroid cancer, and skin cancer after amiodarone therapy. METHODS: Using the Taiwan National Health Insurance Research database, the authors conducted a population-based cohort study. Patients who were treated with amiodarone between 1997 and 2008 were enrolled. Those with antecedent cancer were excluded. Standardized incidence ratios (SIRs) of cancers were calculated to compare the cancer incidence of the study cohort with that of the general population. A multivariate Cox regression model was used to evaluate the association between cumulative defined daily doses (cDDDs) of amiodarone and cancer occurrence. RESULTS: The study included 6418 subjects, with a median follow-up of 2.57 years. A total of 280 patients developed cancer. The risk of cancer increased with borderline significance (SIR, 1.12; 95% confidence interval [95% CI], 0.99-1.26 [P ¼ .067]). Male patients had a higher risk (SIR, 1.18; 95% CI, 1.02-1.36 [P ¼ .022]). The total cohort of patients and the male patients with > 180 cDDDs within the first year were found to have SIRs of 1.28 (95% CI, 1.00-1.61; P ¼ .046) and 1.46 (95% CI, 1.11-1.89; P ¼ .008), respectively. After adjustment for age, sex, and comorbidities, the hazards ratio was 1.98 (95% CI, 1.22-3.22; P ¼ .006) for the high tertile of cDDDs compared with the low tertile. CONCLUSIONS: The results of the current study indicate that amiodarone may be associated with an increased risk of incident cancer, especially in males, with a dose-dependent effect.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2005

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Basalioma after amiodarone therapy-not only in Britain

Cited by 15 publications

References 3 publications

Amiodarone‐induced skin pigmentation and multiple basal‐cell carcinomas

Amiodarone‐induced skin pigmentation and multiple basal‐cell carcinomas

Amiodarone and the risk of cancer

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About